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Abstract: 
 
The optimization of current polymeric nanoparticle therapies is restricted by low drug loadings 
and limited tunability of core properties. To overcome these shortcomings, a novel self-
association approach is utilized to fabricate a dual-loaded poly(1,2-glycerol carbonate)-graft-
succinic acid-paclitaxel (PGC-PTX) conjugate nanoparticle (NP) in which the physical 
entrapment of free paclitaxel (PTX) affords unprecedented ultra-high drug loadings >100 wt%, 
modulation of mechanical stiffness, and tunable release kinetics. Despite high incorporation of 
free PTX (up to 50 wt%), the dual-loaded PGC-PTX nanocarriers (i.e., PGC-PTX + PTX NPs) 
exhibit controlled and sustained drug release over 15 days, without burst release effects. 
Importantly, optimization of drug/material efficiency concomitantly affords improved in 
vitro efficacy. In vivo, PGC-PTX + PTX NPs are safely administered at doses exceeding the 
median lethal dose of standard PTX, while a single high dose significantly extends survival 
relative to weekly PTX administrations in a murine model of peritoneal carcinomatosis. 
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Article:† 
 
The incorporation of chemotherapeutic agents into nanocarriers enhances the safety and efficacy 
of many anticancer agents, but the conundrum remains as to the optimal composition and role(s) 
of the carrier material.1–7 Current research efforts primarily focus on the design of new materials 
and architectures with increased functionality and complexity. However, two outstanding design 
challenges hamper the optimization of nanocarrier mediated drug delivery: (1) maximization of 
drug/material efficiency (i.e., drug loading); and, (2) tunability of nanoparticle (NP) core 
                                                          
† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8nr01978a 
properties. Achieving high drug/material efficiency in the development of drug carriers is 
imperative, as it has the potential to significantly reduce the costs of production, and additionally 
minimizes a patient’s exposure to synthetic carrier material. Control of NP core properties 
enables modulation of mechanical stiffness and release kinetics, affording an opportunity to 
further optimize nanocarrier drug delivery system performance and expand chemotherapy dosing 
protocols. 
 
Polymer–drug conjugate nanocarriers with high drug loadings (i.e., drug : carrier mass ratios) of 
up to 74 wt% have been previously described.8–10 However, these reports demonstrate a robust 
inverse correlation between conjugated drug content and in vitro potency, suggesting that 
increasing drug/material efficiency compromises system efficacy.10,11 Conversely, NPs with 
physically entrapped agents exhibit enhanced in vitro efficacy with increased drug loading.12 
Nanocarriers with physically entrapped agents nonetheless suffer from low drug loadings and 
significant burst release (>50% cumulative release in 24 hours).13 Therefore, the concurrent 
optimization of drug/material efficiency and system efficacy remains elusive. Furthermore, 
release kinetics and particle stiffness are implicated in nanocarrier efficacy.9,11,14–17 However, 
few studies focus on modulating the rate of drug liberation or mechanical stiffness in sustained-
release systems, especially within a single particle design and composition. Herein, we 
demonstrate the mechanical reinforcement of a novel poly(1,2-glycerol carbonate)-graft-succinic 
acid-paclitaxel (PGC-PTX) conjugate nanocarrier via the addition of free paclitaxel (PTX) as a 
drug “binder” to achieve unprecedented ultra-high drug loadings of up to 105 wt%, and to 
modulate PTX release kinetics as well as nanocarrier stiffness. Importantly, increased PTX 
loading results in improved in vitro efficacy, without the need to compromise drug/material 
efficiency. In a murine model of peritoneal carcinomatosis, PGC-PTX NPs with additional 
physically entrapped PTX (i.e., PGC-PTX + PTX NPs) exhibit improved safety at high doses 
and significantly prolong survival even after a single intraperitoneal (IP) injection. 
 
Poly(1,2-glycerol carbonate) (PGC) is chosen as the novel scaffold for PTX conjugation as it 
readily degrades into biocompatible building blocks: glycerol and carbon dioxide.18–20 
Additionally, each repeating unit possesses a functionalizable pendant primary hydroxy, enabling 
high and controlled PTX conjugation of up to 70 mol% or 74 wt%.10 PGC is synthesized by the 
ring-opening copolymerization of benzyl glycidyl ether with carbon dioxide, followed by 
deprotection via high pressure hydrogenolysis.18,21 PGC is then reacted with succinic anhydride 
and 4-dimethylaminopyridine (DMAP) to give PGC-graft-succinic acid (PGC-g-SA).10 PTX is 
subsequently conjugated to PGC via standard coupling chemistry using N,N′-
dicyclohexylcarbodiimide (DCC) and DMAP to afford PGC-PTX with 34 mol% (58 wt%) PTX 
conjugation (Fig. 1a; see ESI† for synthetic details). PTX is bound at the C-2′ hydroxy required 
for its potent cytotoxic activity.10,22,23 Thus, cleavage of PTX via the hydrolysable ester linkages 
affords the active form. Since PGC-PTX exhibits high PTX incorporation, we hypothesized that 
the compatibility (i.e., potential for physicochemical interactions) of free PTX with the PGC-
PTX nanocarrier will enable the physical entrapment of large quantities of free drug, resulting in 
ultra-high PTX loadings. Additionally, due to the increased packing density, as well as non-
covalent interactions between unconjugated and conjugated PTX, we theorized that the free drug 
will act as a binder, enabling modulation of both the mechanical properties and release kinetics 
of the nanocarrier. 
 
 
Figure 1. Structure and formulation of PGC-PTX + PTX NPs. (a) Structure of PGC-PTX 
conjugate. (b) PGC-PTX + PTX NPs are formulated by emulsifying the polymer and free PTX in 
the presence of sodium dodecyl sulfate (SDS). 
 
PGC-PTX + PTX NPs are prepared by emulsification (Fig. 1b). The core components, including 
PGC-PTX and free PTX, are dissolved in dichloromethane, while the surfactant, sodium dodecyl 
sulfate (SDS), is added to phosphate buffer. The mixture of the organic and aqueous solutions is 
then emulsified under an argon blanket via ultrasonication. To ensure the elimination of 
unassociated SDS, the colloidal suspensions are dialyzed for 24 hours in 1 L of phosphate buffer 
using a dialysis membrane with a 10 000 Da molecular weight cut-off. The corresponding 
concentration of SDS during dialysis is <0.01 mg mL−1, which is below its critical micelle 
concentration of 2.3 mg mL−1.24 Given the high solubility of SDS in aqueous media (>100 mg 
mL−1) as well as its low molecular weight (288 Da), unassociated SDS is removed during 
dialysis. PGC-PTX + PTX NPs are formulated with up to 50 wt% additional physically 
entrapped drug, demonstrating the exceptional ability of PGC-PTX nanocarriers to encapsulate 
free PTX. This observation is in stark contrast to the majority of drug carriers, which typically 
achieve <10 wt% drug loading by encapsulation due to less optimal compatibility between drug 
and carrier (Table S1, ESI†). In fact, encapsulation of celecoxib, a different hydrophobic active 
agent with a similar partition coefficient to PTX, does not exceed 10 wt% in PGC-PTX NPs. 
Similarly, poly(benzyl 1,2-glycerol carbonate) (PGC-Bn) NPs exhibit a maximum PTX 
encapsulation of 5 wt%, highlighting the importance of physicochemical interactions between 
free PTX and conjugated PTX. Previous work has likewise demonstrated that increasing the 
compatibility between a drug and its carrier, for example, via the incorporation of aromatic 
groups on the polymer chain, augments drug loading by physical entrapment (up to 35 wt% free 
drug).25–28 
 
PGC-PTX + PTX NPs exhibit sub-100 nm diameters, low dispersity, and negative zeta potentials 
due to the negative charge of the SDS surface coating (Fig. 2a, b and Fig. S4, ESI†). NP size 
does not vary with free PTX loading, confirming the ability of the free drug binder to intersperse 
within the polymer network (Fig. 2a). Likewise, the addition of free PTX does not impact the 
low dispersity of the PGC-PTX + PTX carriers, with all formulations exhibiting low 
polydispersity indices (PDIs) ≤ 0.1 (Fig. S4a, ESI†). PTX encapsulation efficiency (EE), or the 
portion of added free drug that is incorporated in the final NP suspension, exceeds 80% for all 
three formulations (Fig. 2c). Interestingly, EE increases with escalating PTX loading, with the 
average loading efficiency reaching 95% in the 50 wt% formulation. This trend indicates that 
increasing the density of PTX in the nanocarrier further promotes the incorporation of additional 
drug. Importantly, PGC-PTX + PTX NPs are the first demonstration of ultra-high drug loadings 
exceeding 100 wt%. Specifically, drug loading is defined as follows: 
 
Drug loading (wt%) =
𝑚𝑚drug
𝑚𝑚carrier
× 100% 
 
Here, mdrug and mcarrier are the mass of the drug and the mass of the polymer carrier material, 
respectively.25,29,30 Drug loading exceeds 100 wt% when the mass of the drug is greater than the 
mass of the carrier. Due to the high PTX incorporation in the polymer backbone as well as the 
enhanced ability to encapsulate large quantities of drug with high efficiency, PGC-PTX + PTX 
NP drug loading can be tuned from 58 wt% (PGC-PTX NPs) to 105 wt% (PGC-PTX + 50 wt% 
PTX NPs) (Fig. 2d). Resultant PTX concentrations are therefore as high as 20 mg mL−1, 
compared to PTX aqueous solubility of 0.3 μg mL−1.31 
 
Figure 2. Characterization of PGC-PTX + PTX NPs. (a) Dynamic light scattering size 
measurements of PGC-PTX NPs and PGC-PTX + PTX NPs. (b) Scanning electron micrograph 
of PGC-PTX + 50 wt% PTX NPs. (c) Encapsulation efficiency of free PTX. (d) Total PTX 
loading of each NP formulation. Data are presented as the mean ± standard deviation of 3 
independently formulated NP batches per group. 
 
Due to the ability of PGC-PTX NPs to encapsulate free PTX at high density, we hypothesized 
that the free drug effectively reinforces the polymeric nanocarrier network via noncovalent 
interactions with conjugated PTX, rendering the free drug an effective binder for the modulation 
of mechanical properties on the nano-scale. To study nanocarrier mechanical properties, atomic 
force microscopy (AFM) was used to collect force curves, correlating cantilever tip indentation 
depth with force. Typical force curves display two regions with differing slopes (Fig. 3a). The 
initial contact regime, resulting from indentation of the particle surface, reflects the mechanical 
properties of the particle itself. As the tip penetrates deeper into the material, the underlying stiff 
substrate influences the mechanical response, altering the slope of the force curve.32 To obtain 
the elastic modulus of the nanocarriers, the Hertz’s model for non-adhesive elastic contact was 
used to correlate the loading force with indentation depth within the initial contact regime, 
spanning 5–50 pN force and up to 50 nm indentation depth. Increased free PTX loading results 
in significant increases in nanocarrier elastic modulus (≥25 wt% PTX; Fig. 3b). Interestingly, 
this effect is not significant at lower loadings of free PTX (≤10 wt%), illustrating the importance 
of high loading capacity. PGC-PTX NPs and PGC-PTX + PTX NPs with 10, 25, and 50 wt% 
free PTX exhibit elastic moduli of 27.2 ± 9.5, 39.0 ± 9.9, 55.2 ± 23.2, and 94.5 ± 20.1 kPa, 
respectively. These values are within the range of elastic moduli reported for polymers such as 
highly cross-linked polyvinylpyrrolidone (40.8 ± 1.9 kPa),33 highly cross-linked polyacrylamide 
(34.8 ± 1.5 kPa),33 high density poly(N-isopropylacrylamide) (123 ± 9 kPa),34 and agar (40–90 
kPa).35 The ability of PTX to mechanically reinforce the nanocarrier polymer network is 
attributed to increased packing density as well as interactions of the drug with the polymer 
scaffold. Similarly, crystals exhibit high stiffness due to high packing density and molecular 
order. To evaluate the stiffness of highly ordered PTX in the absence of a polymer network, PTX 
crystals were formed by emulsifying a solution of the free drug in an aqueous solution of SDS 
(Fig. S5, ESI†). PTX crystals exhibit an elastic modulus of 796 ± 565 MPa, four orders of 
magnitude greater than the polymeric nanocarrier formulations. Nonetheless, despite their high 
PTX loading, the PGC-PTX + PTX nanocarriers do not exhibit crystallinity as demonstrated by 
differential scanning calorimetry and X-ray powder diffraction analysis, confirming the random 
distribution of PTX within the entangled polymer network (Fig. S6 and S7, ESI†). This result is 
in agreement with previous reports demonstrating the amorphous configuration of active agents, 
including PTX and docetaxel, in polymeric carriers.12,36,37 
 
Figure 3. Nanomechanical characterization of PGC-PTX + PTX NPs. (a) Representative force-
indentation curve of a nanoparticle. The solid line shows the region used for fitting using the 
Hertz’s model. (b) Elastic modulus of NP formulations (***p < 0.001, ****p < 0.0001; 
compared to PGC-PTX NPs). Data are presented as mean ± standard deviation. Example force 
retraction curves showing (c) single extension peak, (d) saw-tooth pattern, and (e) irregular force 
plateau. Insets illustrate the proposed mechanism of polymer chain pulling. 
 
Analysis of AFM retraction curves reveals long-range adhesive interactions between polymer 
chains in the nanocarrier matrix. All PGC-PTX + PTX NPs exhibit rupture lengths on the order 
of 100 nm (Fig. S8, ESI†), while previous size exclusion chromatography measurements 
illustrate that PGC-PTX exhibits an average molecular weight of 9393 Da, corresponding to an 
18-mer with an extended chain-length of approximately 16 nm.10 This result suggests that many 
interacting chains are concurrently pulled by the AFM tip. Individual analysis of force retraction 
curve patterns for each formulation provides additional insight on molecular interactions within 
the polymeric core. While 93% of the retraction curves of PGC-PTX NPs reveal single peaks 
resembling the pulling of a polymer chain (Fig. 3c), 7% show a saw-tooth pattern (Fig. 3d), 
which is typically observed in the unfolding of a structured protein or the unzipping of a polymer 
fiber from a substrate.38,39 In the case of a polymeric nanocarrier, the saw-tooth pattern is likely 
due to the pulling and disruption of multiple, entangled polymer chains. The force extension 
curves of reinforced PGC-PTX + 10 wt% PTX NPs exhibit a greater incidence of saw-tooth 
patterns, at a frequency of 70%, demonstrating increased core interactions in the presence of free 
PTX. An additional 28% of retraction curves exhibit irregular plateau force curves (Fig. 3e), 
while 2% reveal single peaks. Irregular plateau force curves result from stretching of the pulled 
chains, which is required to overcome increased interactions in the entangled polymer 
network.40,41 At 25 wt% free PTX loading, we observe 4% single peak stretching, 50% saw-tooth 
pattern, and 46% irregular plateau force curves. Finally, at the highest free PTX encapsulation of 
50 wt%, we rarely observe extension curves, likely due to decreased adhesion between the tip 
and rigid polymer matrix. Among the few extension curves observed, 6% show single peaks, 
29% show a saw-tooth pattern, and 65% show irregular plateau force curves. Taken together, 
these results demonstrate the tunability of PGC-PTX + PTX nanocarrier mechanical properties as 
a function of physically entrapped PTX, which increases core stiffness and promotes polymer 
matrix stability via the augmentation of core interactions. 
 
Subsequently, PTX release kinetics were evaluated by incubating the NPs in pH 7.4 phosphate 
buffer for 15 days at 37 °C (Fig. 4a, b). At given time-points, aliquots were collected from the 
release media and free PTX content was determined using liquid chromatography-mass 
spectrometry. PGC-PTX NPs and PGC-PTX + PTX NPs with 10, 25, and 50 wt% free PTX 
encapsulation exhibit 24%, 39%, 89%, and 77% cumulative PTX release within 15 days, 
respectively (Fig. 4b). While PGC-PTX + 50 wt% PTX NPs display accelerated drug release at 
early time-points (≤5 days) (Fig. 4a), PGC-PTX + 25 wt% PTX NPs demonstrate greater 
cumulative PTX release at later timepoints (Fig. 4b). This result is likewise attributed to the 
increasing propensity of free PTX to interact with the nanocarrier matrix as overall PTX content 
is increased. Interestingly, scanning electron micrographs of PGC-PTX NPs and PGC-PTX + 50 
wt% PTX NPs after 7 and 15 days of release show that both nanocarrier formulations exhibit a 
decrease in size following PTX release (Fig. S9, ESI†). However, PGC-PTX NPs maintain a 
stable elastic modulus throughout the 15 day release period, while PGC-PTX + 50 wt% PTX 
NPs exhibit significant reductions in stiffness with increased duration of release (Fig. 4c). These 
results are in agreement with the relatively rapid PTX release kinetics of the PGC-PTX + 50 wt% 
PTX NPs compared to the PGC-PTX NPs, and additionally demonstrate that liberation of PTX 
from the PGC-PTX + PTX nanocarrier core reduces core interactions and mechanical stiffness. 
 
 
Figure 4. PGC-PTX + PTX NP release kinetics, nanomechanical characterization following drug 
release, and in vitro cytotoxicity. PTX release kinetics of PGC-PTX NPs and PGC-PTX + PTX 
NPs at 37 °C in pH 7.4 phosphate buffer at (a) early time-points (≤5 days) and (b) over 15 days. 
(c) The elastic moduli of PGC-PTX NPs and PGC-PTX + 50 wt% PTX NPs were characterized 
before and after 7 and 15 days of release (**p < 0.01, ****p < 0.0001; compared to day 0 
control). (d) MSTO-211H cells were incubated with non-drug loaded PGC-Bn NPs, PTX-C/E, or 
one of four NP formulations. Cell viability was evaluated after 5 days of exposure. All 
experiments were performed in triplicate, with data presented as the mean ± standard deviation. 
 
PGC-PTX + PTX NPs exhibit tunable release kinetics, which are modulated by varying the free 
PTX content. Increasing the ratio of unconjugated : conjugated PTX via the physical entrapment 
of free drug affords facilitated release kinetics due to the ability of free PTX to diffuse from the 
polymeric matrix without the need for cleavage from the polymer backbone. However, despite 
the high density of free PTX, an initial burst release is not observed, with all PGC-PTX + PTX 
NP formulations exhibiting sustained drug release due to the compatibility between PTX and the 
PGC-PTX carrier. Additionally, we observe that the elastic modulus of the PGC-PTX + PTX 
NPs decreases with drug release time while the PGC-PTX NPs do not. Burst release kinetics of 
physically entrapped drug can be attenuated by increasing the compatibility between the drug 
and the polymer carrier, for example, via the incorporation of aromatic groups in the polymer 
chain.26,27 The release of conjugated PTX depends on both diffusion and hydrolysis of the drug 
from the polymer backbone. Sustained, linear release kinetics are reported for polymer–drug 
conjugate therapeutics.15,42,43 Classically, surface erosion of a polymer depot containing an 
encapsulated drug affords linear release kinetics.44 Studies are ongoing to further characterize the 
release mechanism of the PGC-PTX + PTX NPs, which likely involves a combination of surface 
and bulk erosion processes. 
 
NP in vitro cytotoxicity was evaluated in MSTO-211H mesothelioma cancer cells after 5 days of 
exposure (Fig. 4d). Cells were treated with PGC-PTX NPs, one of the PGC-PTX + PTX NP 
formulations, the clinical formulation of PTX in a Cremophor EL/ethanol (1 : 1 v/v; C/E) 
excipient (PTX-C/E), or PGC-Bn NPs as a drug-free NP control. Cells treated with drugfree 
PGC-Bn NPs at equivalent PGC backbone concentrations to PGC-PTX NPs exhibit minimal cell 
death, with viabilities exceeding 80% at all concentrations. Due to the sustained release of active 
PTX from the PGC-PTX + PTX nanocarriers over an extended period of time, the in vitro 
potency after 5 days of exposure is reduced relative to PTX-C/E. Nonetheless, in contrast with 
previous reports, PGC-PTX + PTX NP potency increases with greater PTX loading, with PGC-
PTX + 50 wt% PTX NPs (105 wt% total PTX loading) exhibiting the greatest cytotoxic effect 
(Table S2, ESI†). These results also correlate with PGC-PTX + PTX NP release kinetics at early 
time-points (≤5 days), with accelerated drug release resulting in greater in vitro cell killing. 
Therefore, PGC-PTX + PTX NPs afford the concurrent optimization of nanocarrier drug loading 
and efficacy. 
 
To evaluate the effect of rigidity on nanocarrier cellular internalization kinetics, MSTO-211H 
cells were incubated with either fluorescent, rhodamine-labeled PGC-PTX NPs or fluorescent, 
rhodamine-labeled PGC-PTX + 50 wt% PTX NPs. Nanocarrier internalization was subsequently 
monitored over the course of 4 hours via fluorescence activated cell sorting. Cells exhibiting 
greater fluorescence than 99% of the untreated, control population were considered positive for 
NP internalization. Our results demonstrate that the stiffer PGC-PTX + 50 wt% PTX NPs exhibit 
significantly increased cellular uptake at all time-points, with 96% of the cell population 
internalizing PGC-PTX + 50 wt% PTX NPs within 2 hours of treatment (Fig. S10, ESI†). 
Conversely, only 76% of cells internalize PGC-PTX NPs after 4 hours of exposure. This result is 
in agreement with previously published reports demonstrating greater cellular internalization of 
rigid nanocarriers relative to less rigid nanocarriers.16,17 Notably, conflicting reports regarding 
the effect of particle stiffness on cellular internalization warrant further and continued evaluation 
of tunable carriers.45–47 NP cellular internalization, rather than cell surface adhesion, was 
confirmed via laser scanning confocal microscopy (Fig. S11, ESI†). 
 
Due to the high aqueous concentrations of PTX as well as the continuous and sustained drug 
release afforded by the PGC-PTX + PTX nanocarriers, we hypothesized that PGC-PTX + PTX 
NPs can be safely administered at considerably higher PTX doses than PTX-C/E. A single dose 
of 140 mg kg−1 conjugated PTX can be safely administered in mice via PGC-PTX NPs.10 To 
evaluate the safety of the analogous dual-loaded carriers, healthy mice were given a single IP 
injection of PGC-PTX + 25 wt% PTX NPs at a dose of 200 mg kg−1 PTX (140 mg kg−1 
conjugated PTX + 60 mg kg−1 free PTX), and body weight was monitored over the course of two 
weeks post-administration. This formulation was chosen for initial evaluation as it has the 
median free drug loading among the NPs studied. Animals treated with PGC-PTX + 25 wt% 
PTX NPs exhibit an initial 10% reduction in body weight within two days after treatment (Fig. 
S12a, ESI†), rendering 60 mg kg−1 (25 wt%) free PTX the maximum dose that can be safely 
administered. Nonetheless, animal weight increases after day 2 and returns to starting weight by 
day 14. Additionally, histological evaluation of the major organs after 14 days of PGC-PTX + 25 
wt% PTX NP exposure does not reveal any adverse reactions relative to untreated animal 
controls, confirming that the treatment is well-tolerated (Fig. S12b–g, ESI†). Therefore, a large 
dose of 200 mg kg−1 PTX can be safely administered via PGC-PTX + 25 wt% PTX NPs. In 
contrast, the maximum tolerated dose (MTD) of standard PTX-C/E in mice is between 13–50 mg 
kg−1, while the median lethal dose (LD50) is 128 mg kg−1.48–51 
 
 
Figure 5. In vivo efficacy of PGC-PTX + 25 wt% PTX NPs as a single dose in the treatment of 
peritoneal mesothelioma. One week after IP tumor inoculation, mice were treated with saline, a 
single 200 mg kg−1 PTX dose via PGC-PTX + 25 wt% PTX NPs (140 mg kg−1 conjugated PTX + 
60 mg kg−1 free PTX), or weekly 20 mg kg−1 PTX-C/E for up to 10 weeks (total dose control). 
Overall survival was monitored for 8 weeks post-tumor inoculation (n = 8 per group; *p = 
0.0105). Overall survival of animals treated with a single dose of 140 mg kg−1 PTX via PGC-
PTX NPs in a separate study is shown for ref. 10. 
 
While sustained release is desirable for maintaining high local concentrations of active drug and 
minimizing toxicities associated with high peak tissue concentrations, Luo et al. report that 
among three PTX nano-conjugate systems exhibiting sustained release, the system exhibiting the 
most rapid release is the most efficacious in vitro and in vivo.14 Our own results as well as those 
of others likewise demonstrate that accelerated drug release kinetics correlate with improved in 
vitro efficacy.9,15 Due to the continuous and extended PTX release afforded by PGC-PTX 
nanocarriers, we previously demonstrated the utility of PGC-PTX NPs as a single high-dose 
replacement for multi-dose PTX treatment regimens in peritoneal mesothelioma.10 A single IP 
injection of 140 mg kg−1 PTX via PGC-PTX NPs affords comparable survival to PTX 
administered as seven doses of weekly 20 mg kg−1 PTX-C/E.10 However, we hypothesized that 
PGC-PTX + 25 wt% PTX NPs, which exhibit sustained PTX release over a period of 15 days 
compared to 70 days for PGC-PTX NPs, would significantly improve survival compared to the 
equivalent dose of PTX-C/E administered as a multi-dose treatment regimen. One week after IP 
tumor inoculation with luciferase-expressing MSTO-211H (MSTO-211H-luc) cells, mice were 
treated with either saline, a single dose of 200 mg kg−1 PTX via PGC-PTX + 25 wt% PTX NPs 
(140 mg kg−1 conjugated + 60 mg kg−1 unconjugated PTX), or weekly 20 mg kg−1 PTX-C/E for 
up to 10 weeks (total PTX dose equivalent). Due to the toxicity of PTX-C/E, an equivalent single 
high-dose control cannot be administered. Additionally, daily 20 mg kg−1 PTX-C/E 
administrations result in a 63% acute mortality rate.10 Therefore, a total PTX-C/E dose control 
must be administered as a weekly multi-dose treatment regimen. The study was concluded 8 
weeks after tumor inoculation when >90% of control animals succumbed to disease. Animals 
treated with a single dose of PGC-PTX + 25 wt% PTX NPs exhibit significantly improved 
survival compared to multi-dose PTX-C/E treated animals (p = 0.0105; Fig. 5). Similarly, at 4 
and 6 weeks after tumor inoculation, PGC-PTX + 25 wt% PTX NP treated animals exhibit 
visibly reduced tumor burden relative to control groups (Fig. S13, ESI†). Therefore, a single high 
dose of PGC-PTX + 25 wt% PTX NPs extends survival compared to multi-dose PTX-C/E, while 
polymer only PGC-PTX NPs exhibit equivalent efficacy to multi-dose PTX-C/E.10 Given a drug 
release rate of approximately 6% per day (Fig. 4b), PGC-PTX + 25 wt% PTX NP in vivo dosing 
is approximated to be 12 mg kg−1 PTX per day, which is within the therapeutic range employed 
in preclinical investigation.52–54 Accordingly, PGC-PTX + 25 wt% PTX NP treatment is not 
expected to cause drug resistance. Nonetheless, studies are underway to assess the sensitivity of 
tumor cells to PTX treatment following exposure to PGC-PTX + 25 wt% PTX NPs, as well as to 
quantify tumor PTX concentrations following NP treatment. These findings highlight the utility 
of PGC-PTX + 25 wt% PTX NPs in the treatment of peritoneal carcinomatosis, in which the 
implementation of long-term regional chemotherapy is challenging despite demonstrating 
improved outcomes.55,56 
 
Conclusions 
 
In summary, PGC-PTX + PTX nanoassemblies are a distinctive drug delivery system which 
enables unprecedented ultra-high drug loadings >100 wt% via encapsulation of free drug in a 
high density drug-conjugated polymer. NP formulation is robust and reproducible, producing 
uniform sub-100 nm particles. The self-association and physical entrapment of free PTX binder 
affords the modulation of PTX loading, nanocarrier stiffness, and drug release kinetics. Despite 
the high density of free PTX (up to 50 wt%), all PGC-PTX + PTX NP formulations exhibit 
sustained and controlled PTX release over 15 days, without any burst release effects. The 
continuous and sustained release of PTX from PGC-PTX + PTX nanocarriers affords improved 
in vivo safety at high PTX doses exceeding the LD50 of standard PTX-C/E. Importantly, PGC-
PTX + PTX NPs enable the concurrent optimization of drug/material efficiency and system 
efficacy. PGC-PTX + PTX NPs with increased drug loadings exhibit improved in vitro efficacy. 
Similarly, a single high-dose of PGC-PTX + 25 wt% PTX NPs affords significantly improved 
survival in a murine model of peritoneal carcinomatosis compared to a multi-dose PTX-C/E 
treatment regimen, while polymer only PGC-PTX NPs exhibit equivalent efficacy to multi-dose 
PTX-C/E. Notably, these dual-loaded polymer–drug conjugate nanoassemblies present a unique 
platform for the modulation and optimization of nanocarrier properties. The concomitant 
realization of nanocarriers with previously unattainable ultra-high drug loadings, sustained 
release, and in vivo safety at high PTX doses opens new paradigms in the rational design of 
novel drug delivery systems and dosing protocols with transformative clinical potential. 
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